dc.contributor.author | Helvaci, Nafiye | |
dc.contributor.author | Eyupoglu, Nesrin Damla | |
dc.contributor.author | Karabulut, Erdem | |
dc.contributor.author | Yildiz, Bulent Okan | |
dc.date.accessioned | 2021-11-01T15:05:35Z | |
dc.date.available | 2021-11-01T15:05:35Z | |
dc.date.issued | 2021 | |
dc.identifier.issn | 1664-2392 | |
dc.identifier.uri | https://doi.org/10.3389/fendo.2021.598249 | |
dc.identifier.uri | https://hdl.handle.net/11491/7335 | |
dc.description.abstract | Background and Objective Obesity has been reported as a risk factor for adverse outcomes in COVID-19. However, available studies presenting data on obesity prevalence in patients with COVID-19 have conflicting results. The objective of this systematic review and meta-analysis is to evaluate the prevalence of obesity in these patients and to stratify the estimates by illness severity. Methods We performed a literature search with the use of Medline/PubMed and Google Scholar database from December 1, 2019 to June 27, 2020 and systematically reviewed studies reporting the number of obese patients with real-time reverse transcriptase polymerase chain reaction (rRT-PCR)-confirmed SARS-CoV-2 infection. Results Nineteen studies were identified. The pooled obesity prevalence rates were 0.32 (95% CI: 0.24-0.41) in hospitalized patients, 0.41 (95% CI: 0.36-0.45) in patients admitted to intensive care unit, 0.43 (95% CI: 0.36-0.51) in patients needing invasive mechanic ventilation (IMV), and 0.33 (95% CI: 0.26-0.41) in those who died. Obesity was associated with a higher risk for hospitalization [Odds ratio (OR): 1.3, 95% CI: 1.00-1.69; I-2 52%, p = 0.05], ICU admission (OR: 1.51, 95% CI: 1.16-1.97; I-2 72%, p = 0.002), and IMV requirement (OR: 1.77, 95% CI: 1.34-2.35; I-2 0%, p < 0.001). The increase in risk of death did not reach statistical significance (OR: 1.28, 95% CI: 0.76-2.16, p = 0.35) which might be due to obesity survival paradox and/or unidentified factors. Conclusions Our data indicate that obese subjects may be at higher risk for serious illness if infected and obesity may play a role in the progression of COVID-19. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Frontiers Media Sa | en_US |
dc.relation.ispartof | Frontiers In Endocrinology | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | obesity | en_US |
dc.subject | body mass index | en_US |
dc.subject | COVID-19 | en_US |
dc.subject | SARS-CoV-2 | en_US |
dc.subject | prognosis | en_US |
dc.title | Prevalence of Obesity and Its Impact on Outcome in Patients With COVID-19: A Systematic Review and Meta-Analysis | en_US |
dc.type | review | en_US |
dc.department | [Belirlenecek] | en_US |
dc.authorid | Yildiz, Bulent O. / 0000-0003-1797-7662 | |
dc.identifier.volume | 12 | en_US |
dc.relation.publicationcategory | Diğer | en_US |
dc.department-temp | [Helvaci, Nafiye] Hitit Univ, Dept Internal Med, Div Endocrinol & Metab, Sch Med, Corum, Turkey; [Eyupoglu, Nesrin Damla; Yildiz, Bulent Okan] Hacettepe Univ, Dept Internal Med, Div Endocrinol & Metab, Sch Med, Ankara, Turkey; [Karabulut, Erdem] Hacettepe Univ, Sch Med, Dept Biostat, Ankara, Turkey | en_US |
dc.contributor.institutionauthor | [Belirlenecek] | |
dc.identifier.doi | 10.3389/fendo.2021.598249 | |
dc.authorwosid | Yildiz, Bulent O. / ABD-7781-2020 | |
dc.description.wospublicationid | WOS:000627361000001 | en_US |
dc.description.scopuspublicationid | 2-s2.0-85102373549 | en_US |
dc.description.pubmedpublicationid | PubMed: 33716962 | en_US |